NEXGEL, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXGL research report →
Price Chart
About the company
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology.
- CEO
- Brian J. Kieser
- IPO
- 2021
- Employees
- 19
- HQ
- Langhorne, PA, US
Get TickerSpark's AI analysis on NXGL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.67M
- P/E
- -0.25
- Fwd P/E
- 8.92
- PEG
- 0.00
- P/S
- 0.17
- P/B
- 0.21
- EV/EBITDA
- -2.72
- Div Yield
- 0.00%
- Gross Margin
- 33.42%
- Op Margin
- -58.61%
- Net Margin
- -53.97%
- ROE
- -119.74%
- ROIC
- -51.22%
Latest fiscal year · YoY change
- Revenue
- $11.42M+31.5%
- Gross Profit
- $4.51M+64.1%
- Op Income
- $-3,352,000
- Net Income
- $-3,000,000+8.6%
- EPS
- $-7.64+24.2%
- OCF Growth
- +66.1%
- FCF Growth
- +68.0%
- 52W High
- $40.40
- 52W Low
- $3.00
- 50D MA
- $4.32
- 200D MA
- $10.68
- Beta
- 0.81
- RSI (14)
- 41
- Avg Volume
- 112.35K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NEXGEL said Q1 revenue was relatively flat year over year, but management highlighted a newly closed BioNX acquisition that it says could roughly triple annual revenue and turn the company immediately accretive.· May 15, 2026
- Q1 revenue was $2.65 million vs. $2.81 million a year ago, with Silly George weakness partly offset by contract manufacturing and MEDAGEL growth.
- SG&A rose mainly because of BioNX acquisition-related costs and the Kiss Nail Products legal case, which management said has since been settled.
- Cash and restricted cash were about $2.1 million at March 31, 2026, and $1.8 million as of the call; the company said it raised $13.8 million total for the acquisition and working capital.
- BioNX did not contribute revenue in Q1; management said revenue from the acquisition should begin to be reflected for about half of Q2.
- Management said the pro forma business could reach roughly $35 million in annual revenue and be immediately accretive to profitability upon closing.
NEXGEL reported first-quarter 2026 revenue of $2.65 million, down from $2.81 million in the same period last year. Management described the business as relatively flat year over year, with lower Silly George sales partly offset by growth in contract manufacturing and MEDAGEL. Cash and restricted cash were approximately $2.1 million at March 31, 2026, and cash on hand was $1.8 million at the time of the call. The company said it raised $13.8 million in total, including $8.8 million in cash and a $5 million convertible note delivered to Celularity, to fund the acquisition and working capital. No BioNX revenue was included in Q1, and management expects to start recognizing acquisition revenue for about half of Q2. No EPS or gross margin figures were stated.
Adam Levy framed the quarter around integration progress and the strategic importance of the BioNX deal. He said the acquisition adds six commercial regenerative biomaterial products, three 510(k) devices in development, and an expanded team that should strengthen both manufacturing and commercialization capabilities. His tone was constructive and optimistic, emphasizing that the transaction is a “step change” for NEXGEL and that the company is focused on building a platform for sustained long-term growth and profitability.
Ian Blackman, in his first public comments as CFO, said the normalized operating overhead is an approximate monthly run rate of $500,000 all-in for salaries, marketing, commissions, and related costs. Levy also said the company’s cash on hand had fallen to $1.8 million as of the call after funding the BioNX transaction, and that Sequence LifeScience’s $5.5 million investment improved the financing structure and replaced a near-term lender with a long-term strategic partner. Management said the acquisition-related costs had lifted SG&A in Q1, but the first quarter did not include any revenue from BioNX.
Analysts and investors focused on how quickly BioNX can ramp after closing, how the company’s legacy businesses are performing, and whether the offering was essentially finished. Levy said sales activity only really restarted around May 15 because contracts, training, vendor changes, and hospital account updates had to be completed first. On the legacy side, he said Silly George was weaker than expected but was already recovering in April, iRhythm had become a steady but not yet large customer, and other funnel opportunities still exist though 510(k) timing makes quarter-by-quarter forecasting difficult.
The bull case is that BioNX materially expands NEXGEL’s scale with commercial products, reimbursement pathways, and access to roughly 500 hospitals, while management says it can nearly triple revenue to about $35 million. Management also pointed to a recovery in Silly George, growth in contract manufacturing and MEDAGEL, and a strategic partner in Sequence LifeScience that adds manufacturing, product development, and distribution support.
The main risks are execution and timing: BioNX revenue had not yet ramped because the field force was only just reengaging, and Q1 still showed flat revenue despite prior growth expectations. Cash remains limited at $1.8 million, operating overhead is rising, and management said several growth initiatives depend on 510(k) clearance timing and on whether consumer products and customer programs like iRhythm scale as hoped.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.9%
- Shares Outstanding
- 536.11K
- Float Shares
- 460.61K
of shares held by institutions
18 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 123.06K | ▼ 548 |
| Morgan Stanley | 90.69K | ▲ 35.72K |
| Susquehanna International Group, Llp | 85.14K | ▲ 85.14K |
| Virtu Financial LLC | 79.13K | ▲ 79.13K |
| Geode Capital Management, LLC | 71.32K | ▼ 546 |
| Vanguard Capital Management LLC | 48.92K | 0 |
| Citadel Advisors LLC | 40.98K | ▲ 40.98K |
| Vanguard Fiduciary Trust Co | 34.04K | 0 |
| Jane Street Group, LLC | 25.30K | ▲ 4.69K |
| Stonex Group Inc. | 20.07K | ▲ 20.07K |
| State Street Corp | 17.26K | 0 |
| Northern Trust Corp | 13.43K | ▲ 13.43K |
Held by 9 ETFs
Biggest fund positions in NXGL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Kieser Brian Joseph | other | 1,000,000 |
| Nov 10, 26 | Kieser Brian Joseph | other | 229,167 |
| Nov 10, 26 | Kieser Brian Joseph | other | 181,819 |
| Nov 10, 26 | Kieser Brian Joseph | buy | 133,216 |
| Nov 10, 26 | Kieser Brian Joseph | buy | 133,216 |
| Nov 10, 26 | Kieser Brian Joseph | other | 41,667 |
| Nov 10, 26 | Kieser Brian Joseph | sell | 41,667 |
| Nov 10, 26 | Kieser Brian Joseph | sell | 229,167 |
| Nov 10, 26 | Kieser Brian Joseph | sell | 458,334 |
| Nov 10, 26 | Ciardiello Steven | other | 4,546 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NXGL coverage
Recent articles, reports, and earnings notes.
No research on NXGL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXGL report →NEXGEL Postpones Third Quarter 2026 Financial Results and Corporate Update Conference Call to November 24th
globenewswire.com · Nov 19
NEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital Funding
globenewswire.com · Nov 11
NEXGEL Regains Compliance with Nasdaq Listing Requirement
globenewswire.com · Oct 27
NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript
seekingalpha.com · Sep 24
NEXGEL Announces Dial-In Details for Investor Update Call
globenewswire.com · Sep 23
NEXGEL Announces Date for Investor Update Call
globenewswire.com · Sep 16
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
globenewswire.com · Aug 20
NEXGEL Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.